Poolbeg Pharma (LSE:POLB) has revealed that it will serve as the principal industry partner in the RISE programme, an ambitious initiative led by The University of Manchester and The Christie NHS Foundation Trust to study Cytokine Release Syndrome (CRS) triggered by cancer immunotherapies. Backed by a £3.4 million Medical Research Council grant, the programme incorporates the POLB 001 TOPICAL trial and is designed to improve both the safety profile and clinical use of next-generation cancer immunotherapies. The collaboration — which includes major partners such as Johnson & Johnson — underscores the rising urgency to better manage CRS, a key challenge limiting the wider rollout of these transformative treatments.
More about Poolbeg Pharma Ltd.
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company aiming to reshape the cancer immunotherapy landscape. Its lead programme, POLB 001, is being developed to reduce or prevent Cytokine Release Syndrome (CRS), a dangerous immune overreaction, with the goal of enabling cancer immunotherapies to be administered more safely and more widely. The company is also advancing an oral encapsulated GLP-1 therapy intended to offer a more patient-friendly approach to obesity treatment while addressing substantial market demand and critical unmet medical needs.
Leave a Reply